Rapid expansion of intravitreal drug injection procedures, 2000 to 2008: A population-based analysis

Archives of Ophthalmology

Volumn 128, Issue 3, 2010, Pages 359-362

  Campbell, Robert J ^a,c   Bronskill, Susan E ^c   Bell, Chaim M ^c,d   Paterson, J Michael ^c,e   Whitehead, Marlo ^a,c   Gill, Sudeep S ^a,b,c  

^a QUEEN S UNIVERSITY   (Canada)

^b St Mary's of the Lake Hospital   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; DATA BASE; HEALTH PROGRAM; HUMAN; POPULATION RESEARCH; PRIORITY JOURNAL; RETINA MACULA AGE RELATED DEGENERATION;

ANGIOGENESIS INHIBITORS; DRUG DELIVERY SYSTEMS; HEALTH SERVICES RESEARCH; HUMANS; INJECTIONS; INSURANCE CLAIM REVIEW; MACULAR DEGENERATION; ONTARIO; OPHTHALMOLOGY; PHYSICIAN'S PRACTICE PATTERNS; RETROSPECTIVE STUDIES; UNIVERSAL COVERAGE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VITREOUS BODY;

EID: 77749307389     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2010.19     Document Type: Article

References (13)

1. Jager RD, Mieler WF, Miller JW. Age-related macular degeneration. N Engl J Med. 2008;358(24):2606-2617.
2. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355 (14):1419-1431.
3. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab vs verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006; 355(14):1432-1444.
4. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
5. Williams JI, Young W. A summary of studies on the quality of health care administrative databases in Canada. In: Goel V, Williams J, Anderson G, Blackstien-Hirsch P, Fooks C, Naylor D, eds. Patterns of Health Care in Ontario: The ICES Practice Atlas. 2nd ed. Ottawa, ON: Canadian Medical Association; 1996:339-345. http://www.ices.on.ca/file/Practice2-appendix.pdf. Accessed May 14, 2009.
6. Cunningham MA, Edelman JL, Kaushal S. Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol. 2008;53(2):139-149.
7. Hatch WV, Cernat G, Wong D, Devenyi R, Bell CM. Risk factors for acute endophthalmitis after cataract surgery: a population-based study. Ophthalmology. 2009;116(3):425-430.
8. Health Canada. Reports of eye inflammation, endophthalmitis, and toxic anterior segment syndrome (TASS) following off-label intravitreal use of Avastin (bevacizumab) - for health professionals. http://www.hc-sc.gc.ca/dhp-mps/medeff /advisories-avis/prof/-2008/avastin-4-hpc-cps-eng.php. Accessed May 14, 2009.
9. National Eye Institute. Comparison of age-related macular degeneration treatments trials: Lucentis-Avastin trial. Clinicaltrials.govWebsite. http://www.clinicaltrials .gov/ct2/show/NCT00593450?term= macular+degeneration+catt&rank=1. Accessed May 14, 2009.
10. Canadian Institute for Health Information. Surgical Volume Trends, 2008: Within and Beyond Wait Time Priority Areas. Ottawa, ON: Canadian Institute for Health Information; 2008. http://secure.cihi.ca/cihiweb/products/ surgical-volume-trends-2008-en.pdf. Accessed May 14, 2009.
11. Bellan L, Buske L. Ophthalmology human resource projections: are we heading for a crisis in the next 15 years? Can J Ophthalmol. 2007;42(1):34-38.
12. Hsu J. Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol. 2007;18(3):235-239.
13. Patel PJ, Bunce C, Tufail A; ABC Trial Investigators. A randomised, double-masked phase III/IV study of the efficacy and safety of Avastin (bevacizumab) intravitreal injections compared to standard therapy in subjects with choroidal neovascularisation secondary to age-related macular degeneration: clinical trial design. Trials. 2008;9:56.